VisionIAS Logo
Share
abc
News Today Logo
SUN MON TUE WED THU FRI SAT
1 2 3 4 No article 5 6 7 8 9 10 11 No article 12 13 14 15 16 17 18 No article 19 20 21 22 23 24 25 No article 26 27 28 29

Table of Content

Posted 07 Feb 2024

Updated 18 Mar 2024

2 min read

  • NexCAR19 has been developed by ImmunoAct, a company incubated under IIT Bombay, and Tata Memorial Hospital.
    • NexCAR19 was granted market authorization by Central Drugs Standard Control Organisation (CDSCO) in 2023.
  • CAR-T cell therapy is a new approach in immunotherapy, where the patient’s immune system is strengthened to attack cancer cells. 

 

 

  • It restores the ability of the T-cells to recognise the cancer cells and kill them. 
    • T-cells are white blood cells that recognize and fight infections and cancerous growths. 
    • In advanced stages, cancer cells can inactivate T-cells or modify themselves so that T-cells cannot detect them. 
  • Therapy involves genetic engineering of T-cells by introducing Chimeric Antigen Receptors (CARs), to produce CAR T-cells. 
    • CARs are proteins that assist T-cells to recognise and attach to a specific protein, or antigen, present on cancer cells. 

 

  • Significance of CAR-T cell therapy:
    • Very effective against some types of cancer e.g. Leukemia, Lymphoma.
    • Short treatment time and more rapid recovery as unlike chemotherapy, it is administered only once to a patient.
    • Useful for cancers not responding to combinations of chemotherapy or other immunotherapy approaches.
    • CAR T-cells are known as living drugs as T-cells persist in the body for long-term and can benefit for many years. 
  • Tags :
  • Cancer
  • CAR-T cell therapy
Next Article
Amendments to Food Safety Regulations
Watch News Today
Download News Today
Article Page Bottom Banner
Width resize handle
Height resize handle

Search Notes

Filter Notes

No notes yet

Create your first note to get started.

No notes found

Try adjusting your search criteria.

Subscribe for Premium Features